MoneyWorks4Me

USFDA concludes inspection at Ajanta Pharma’s Paithan manufacturing facility

22 Apr 2026 Evaluate

United States Food and Drug Administration (USFDA) has concluded inspection at Ajanta Pharma’s manufacturing facility at Paithan, in Maharashtra. The inspection was conducted from April 13, 2026, to April 21, 2026, and closed with the issuance of Form-483 with 5 observations. The Company will respond to the US FDA within the stipulated timeline.

Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.

Peers
Company Name CMP
Sun Pharma. Inds. 1861.75
Dr. Reddys Labs. 1172.60
Cipla 1379.35
Lupin 2079.45
Zydus Lifesciences 1137.05
View more..